Loading…
Chinese vaccine developer based in Chengdu; specific vaccine product line not fully established from available knowledge.
Chinese vaccine developer based in Chengdu; specific vaccine product line not fully established from available knowledge.
Moat: none
Headquarters: Chengdu, China · Employees: 451
Size Chengdu Olymvax Biopharmaceuticals (688319.SS) is a China Health Care company (Biotechnology) with a market value of $1.71B, the 1456th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥28.19 on 6 Nov 2026.
Performance Over six months the shares fell 8.7%, against -4.4% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 18 in its peer set.
Growth Revenue grew 12.3% over the last twelve months (peer median +21.1%); the operating margin is 8.2% (peer median -171.6%).
Valuation It trades at 14.8× enterprise value to sales against a peer median of 19.4× (8th cheapest of 18).
Capital Return on invested capital runs 5.5 points below its cost of capital (11.5% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥796M | CN¥702M | CN¥587M | CN¥494M | CN¥544M |
| Revenue growth | — | +19% | +19% | -9% | — |
| Gross profit | CN¥746M | CN¥624M | CN¥532M | CN¥443M | CN¥488M |
| EBITDA | n/a | CN¥76.0M | CN¥57.4M | CN¥37.6M | CN¥43.3M |
| Net income | -CN¥32.0M | CN¥22.3M | CN¥20.8M | CN¥17.6M | CN¥26.6M |
| Free cash flow | -CN¥106M | CN¥7.18M | -CN¥216M | -CN¥125M | -CN¥222M |
| Capital expenditure | CN¥125M | CN¥98.8M | CN¥207M | CN¥170M | CN¥201M |
| Total debt | CN¥509M | CN¥433M | CN¥362M | CN¥238M | CN¥139M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688319.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.6% | -9.9% | 8th highest of 20 |
| 6-month return | -8.7% | -4.4% | 7th lowest of 18 |
| Distance from 52-week high | -37.2% | -38.7% | 9th highest of 20 |
| Revenue growth (TTM) | +12.3% | +21.1% | 6th lowest of 19 |
| Operating margin | 8.2% | -171.6% | 2nd highest of 19 |
| EV / Sales | 14.8× | 19.4× | 8th cheapest of 18 |
| ROIC minus cost of capital | -5.5 pp | -19.3 pp | 2nd highest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | 15.2× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | 1,588.4× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |